151 related articles for article (PubMed ID: 20593273)
1. Synthetic and natural TLR4 agonists as safe and effective vaccine adjuvants.
Fox CB; Friede M; Reed SG; Ireton GC
Subcell Biochem; 2010; 53():303-21. PubMed ID: 20593273
[TBL] [Abstract][Full Text] [Related]
2. Synthetic Toll-like receptor 4 agonist enhances vaccine efficacy in an experimental model of toxic shock syndrome.
Morefield GL; Hawkins LD; Ishizaka ST; Kissner TL; Ulrich RG
Clin Vaccine Immunol; 2007 Nov; 14(11):1499-504. PubMed ID: 17715328
[TBL] [Abstract][Full Text] [Related]
3. TLR4 agonists as immunomodulatory agents.
Alderson MR; McGowan P; Baldridge JR; Probst P
J Endotoxin Res; 2006; 12(5):313-9. PubMed ID: 17059695
[TBL] [Abstract][Full Text] [Related]
4. Toll-like receptor 4 agonists adsorbed to aluminium hydroxide adjuvant attenuate ovalbumin-specific allergic airway disease: role of MyD88 adaptor molecule and interleukin-12/interferon-gamma axis.
Bortolatto J; Borducchi E; Rodriguez D; Keller AC; Faquim-Mauro E; Bortoluci KR; Mucida D; Gomes E; Christ A; Schnyder-Candrian S; Schnyder B; Ryffel B; Russo M
Clin Exp Allergy; 2008 Oct; 38(10):1668-79. PubMed ID: 18631348
[TBL] [Abstract][Full Text] [Related]
5. Adjuvants containing natural and synthetic Toll-like receptor 4 ligands.
Ireton GC; Reed SG
Expert Rev Vaccines; 2013 Jul; 12(7):793-807. PubMed ID: 23885824
[TBL] [Abstract][Full Text] [Related]
6. Enhancement of antigen-specific immunity via the TLR4 ligands MPL adjuvant and Ribi.529.
Evans JT; Cluff CW; Johnson DA; Lacy MJ; Persing DH; Baldridge JR
Expert Rev Vaccines; 2003 Apr; 2(2):219-29. PubMed ID: 12899573
[TBL] [Abstract][Full Text] [Related]
7. TLR9 agonists as adjuvants for prophylactic and therapeutic vaccines.
Daubenberger CA
Curr Opin Mol Ther; 2007 Feb; 9(1):45-52. PubMed ID: 17330401
[TBL] [Abstract][Full Text] [Related]
8. AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity.
Didierlaurent AM; Morel S; Lockman L; Giannini SL; Bisteau M; Carlsen H; Kielland A; Vosters O; Vanderheyde N; Schiavetti F; Larocque D; Van Mechelen M; Garçon N
J Immunol; 2009 Nov; 183(10):6186-97. PubMed ID: 19864596
[TBL] [Abstract][Full Text] [Related]
9. Monophosphoryl lipid A analogues with varying 3-O-substitution: synthesis and potent adjuvant activity.
Jiang ZH; Budzynski WA; Qiu D; Yalamati D; Koganty RR
Carbohydr Res; 2007 May; 342(6):784-96. PubMed ID: 17300769
[TBL] [Abstract][Full Text] [Related]
10. Characterization of the structure and immunostimulatory activity of a vaccine adjuvant, de-O-acylated lipooligosaccharide.
Han JE; Wui SR; Kim KS; Cho YJ; Cho WJ; Lee NG
PLoS One; 2014; 9(1):e85838. PubMed ID: 24465739
[TBL] [Abstract][Full Text] [Related]
11. Bacterial lipopolysaccharides and innate immunity.
Alexander C; Rietschel ET
J Endotoxin Res; 2001; 7(3):167-202. PubMed ID: 11581570
[TBL] [Abstract][Full Text] [Related]
12. TLR4 and MyD88 control protection and pulmonary granulocytic recruitment in a murine intranasal RSV immunization and challenge model.
Cyr SL; Angers I; Guillot L; Stoica-Popescu I; Lussier M; Qureshi S; Burt DS; Ward BJ
Vaccine; 2009 Jan; 27(3):421-30. PubMed ID: 19013492
[TBL] [Abstract][Full Text] [Related]
13. Monophosphoryl lipid A as an adjuvant. Past experiences and new directions.
Ulrich JT; Myers KR
Pharm Biotechnol; 1995; 6():495-524. PubMed ID: 7551233
[TBL] [Abstract][Full Text] [Related]
14. Monophosphoryl lipid A is an lipopolysaccharide-derived Toll-like receptor 4 agonist which may improve Alzheimer's disease pathology.
Wang DB
Expert Opin Biol Ther; 2013 Dec; 13(12):1639-41. PubMed ID: 24074146
[TBL] [Abstract][Full Text] [Related]
15. The science of vaccine adjuvants: advances in TLR4 ligand adjuvants.
Reed SG; Hsu FC; Carter D; Orr MT
Curr Opin Immunol; 2016 Aug; 41():85-90. PubMed ID: 27392183
[TBL] [Abstract][Full Text] [Related]
16. Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents.
Baldridge JR; McGowan P; Evans JT; Cluff C; Mossman S; Johnson D; Persing D
Expert Opin Biol Ther; 2004 Jul; 4(7):1129-38. PubMed ID: 15268679
[TBL] [Abstract][Full Text] [Related]
17. Host factors impacting the innate response in humans to the candidate adjuvants RC529 and monophosphoryl lipid A.
Tiberio L; Fletcher L; Eldridge JH; Duncan DD
Vaccine; 2004 Mar; 22(11-12):1515-23. PubMed ID: 15063577
[TBL] [Abstract][Full Text] [Related]
18. Synthetic TLR4-active glycolipids as vaccine adjuvants and stand-alone immunotherapeutics.
Johnson DA
Curr Top Med Chem; 2008; 8(2):64-79. PubMed ID: 18289078
[TBL] [Abstract][Full Text] [Related]
19. Physicochemical characterization and biological activity of synthetic TLR4 agonist formulations.
Anderson RC; Fox CB; Dutill TS; Shaverdian N; Evers TL; Poshusta GR; Chesko J; Coler RN; Friede M; Reed SG; Vedvick TS
Colloids Surf B Biointerfaces; 2010 Jan; 75(1):123-32. PubMed ID: 19748238
[TBL] [Abstract][Full Text] [Related]
20. Enhanced humoral and Type 1 cellular immune responses with Fluzone adjuvanted with a synthetic TLR4 agonist formulated in an emulsion.
Baldwin SL; Shaverdian N; Goto Y; Duthie MS; Raman VS; Evers T; Mompoint F; Vedvick TS; Bertholet S; Coler RN; Reed SG
Vaccine; 2009 Oct; 27(43):5956-63. PubMed ID: 19679214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
